Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
(NASDAQ:SNY) Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Related Questions
How will the approval of Wayrilz affect Sanofi's revenue forecasts and earnings guidance?
What competitive advantages does Wayrilz provide compared to existing ITP therapies and other BTK inhibitors in development?
Will this approval drive changes in analyst ratings or target prices for Sanofi's stock (SNY) in the short and medium term?